All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-06-29T09:55:37.000Z

What are the main advances in patient care that we are seeing with novel agents for leukemia? #ASCO21

By Joshua Reid, Camilla Rossi
Featured
Jorge Cortes
Jun 29, 2021
Share:

Bookmark this article

During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Jorge Cortes, Augusta University, Augusta, US. We asked, What are the main advances in patient care that we are seeing with novel agents for leukemia?

What are the main advances in patient care that we are seeing with novel agents for leukemia?

Cortes begins by outlining two practice-changing trials and their encouraging response rates. The first being the ZUMA-3 (utilizing CAR T-cell therapy), and the second investigating lintuzumab regimes in adult Philadelphia chromosome-positive ALL patients. He goes on to review two further studies investigating inotuzumab and the value of assessing MRD in patients.

 

More about...
Antibody therapyASCO 2021Conjugated antibodiesInotuzumab ozogamicinlintuzumabPhiladelphia chromosome-positive / BCR-ABL1ZUMA 3

Related articles

Add bookmark

Educational theme | Sequencing and combining immunotherapies in ALL

In this educational theme article, we review the current landscape of the antigen-targeted therapies, blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, and discuss...

May 9, 2023
Add bookmark

Educational theme | Sequencing and combining immunotherapies in ALL

In this educational theme article, we review the current landscape of the antigen-targeted therapies, blinatumomab, inotuzumab...

May 9, 2023
Add bookmark

The current treatment landscape of acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is a rare hematological disorder with a bimodal incidence in childhood and in older adults. The advent of multiple chemotherapies has drastically...

Aug 25, 2020
Add bookmark

The current treatment landscape of acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is a rare hematological disorder with a bimodal incidence in childhood and in older adults. The...

Aug 25, 2020

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox